ClinicalTrials.gov
public full text
Public Domain
CD5CAR-NK Cells for Refractory Invasive Mold Disease
CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD). The study population consists of patients aged ≥18 years with refractory mold infections. The number of patients treated will be 10. This is a dose-escalation study including 3 cohorts.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites#1295876
- Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer#832998
- Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma#1164439
- A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue#353272
- An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies#980897
Record · ID 1295578
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive